BioSpace News Archive

Second-Quarter 2019 Net Sales of $320.6 Million Increased 6 Percent; Second-Quarter 2019 GAAP Net Loss of $5.1 Million; Adjusted EBITDA of $124.1 Million

Nasdaq has granted the Company’s request for continued listing of the Company’s stock on the Nasdaq Stock Market.

The global seborrheic keratosis treatment market size is poised to reach USD 634 million by 2023, according to a new report by Technavio, progressing at a CAGR of 6% during the forecast period.

The Co-operators and BDC Capital co-lead investment that will expand AI-driven infectious disease global early warning system

Shareholder rights law firm Johnson Fistel, LLP has launched an investigation into whether the board members of Cambrex Corporation breached their fiduciary duties in connection with the proposed sale of the Company to private equity firm Permira.

The Hyundai Hope On Wheels non-profit embarks on a nationwide tour this Summer to award new grants for pediatric cancer, surpassing $160 million in lifetime funding for research [07-August-2019] LAS VEGAS , Aug. 7, 2019 /PRNewswire/ -- Hyundai Hope On Wheels® (HHOW), a 501(c)(3) non-profit organization supported by Hyundai and its U.S. dealers, announces

Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced financial results for the second quarter and six months ended June 30, 2019 and provided a corporate update.

Check-Cap Ltd. (the “Company” or “Check-Cap”) (NASDAQ: CHEK) (NASDAQ: CHEKW), (NASDAQ: CHEKZ), a clinical stage medical diagnostics company advancing the development of C-Scan®, the first and only preparation-free ingestible capsule based system for the prevention of colorectal cancer through the detection of precancerous polyps, today announced financial results for the second quarter and six months ended June 30, 2019.

Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s New Drug Application (NDA) for avapritinib

Berkeley Lights, Inc. (BLI), a pioneer and leader in digital cell biology, today announced the appointment of Sarah Boyce, President of Akcea Therapeutics to the Berkeley Lights’ board of directors.